StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.31−0.45 (-3.27%)

Close on Nov 18, 2026Market cap $882.44MP/E –Yield 0.00%

Latigo Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Latigo Biotherapeutics

Latigo Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Latigo Biotherapeutics figures

See a number that looks wrong?